Epetraborole HCl
This active molecular is a selective leucyl-tRNA synthetase inhibitor under the development of Anacor Pharmaceuticals and GlaxoSmithKline as a novel boron-containing antibiotic. Epetraborole was applicated in treatment of infections caused by multidrug-resistant Gram-negative pathogens. All Clostridium perfringens strains had Epetraborole MICs of >32 μg/ml. In Oct 2012, Phase-II for Urinary tract infections in Russia was discontinued. In Mar 2013, Phase-II for Gram-negative infections in USA was Suspended.
| Supplier | BOC Sciences |
|---|---|
| Product # | 1234563-16-6 |
| Pricing | Inquire |
| Cas | 1234563-16-6 |
| Molecular Weight | 373.52 |
| Molecular Formula | C11H17BClNO4 |
| Canonical SMILES | B1(C2=C(C=CC=C2OCCCO)C(O1)CN)O.Cl |